Literature DB >> 30527193

Prediagnosis weight loss, a stronger factor than BMI, to predict survival in patients with lung cancer.

Hugues Morel1, Bruno Raynard2, Michel d'Arlhac3, Pierre-Alexandre Hauss4, Emmanuelle Lecuyer5, Gérard Oliviero6, Clothilde Marty7, Jean-Pierre Gury8, Bernard Asselain9, Michel Grivaux10, Didier Debieuvre11.   

Abstract

OBJECTIVES: Recent studies have demonstrated that elevated BMI is associated with improved survival in patients with lung cancer. According to the authors, this "obesity paradox" could be a true benefit or a spurious relationship. In this context, data from the French KBP-2010-CPHG cohort (7,051 patients followed up for primary lung cancer diagnosed in 2010 in the respiratory medicine departments of 104 nonacademic hospitals) were analyzed.
METHODS: Patients were stratified according to BMI at diagnosis using the definition of the French-Speaking Society of Clinical Nutrition and Metabolism (Société Francophone de Nutrition Clinique et Métabolisme). Survival was analyzed using log-rank and a univariate Cox model. Prognostic factors were identified using a multivariate Cox model with backward elimination procedure, and with or without inclusion of prediagnosis weight loss in the model.
RESULTS: Patients were followed for a median 20.2 months. At diagnosis, respectively 12%, 28%, 45%, and 15% of the 6,595 patients with BMI data were obese, overweight, normal-weight, and underweight; 35%, 43%, 57%, and 75% reported prediagnosis weight loss (i.e., weight loss within the 3 months prior to diagnosis). One-year survival (% [95% CI]) was 53% [50%-57%], 50%, [48%-52%], 43%, [42%-45%], and 32% [29%-35%] in obese, overweight, normal-weight, and underweight patients, respectively (p < 0.001). It was particularly low in underweight patients with prediagnosis weight loss: 27% [24-30%]. BMI did not remain an independent prognostic factor associated with survival when prediagnosis weight loss was introduced in the Cox model. Risk of death was increased by 17%, 23%, and 46% in patients with <5 kg, 5-10 kg, or ≥10 kg prediagnosis weight loss, respectively (p < 0.001).
CONCLUSION: BMI is an easy but crude assessment tool. Other variables should be used to improve management of patients, and understanding of how prediagnosis body size and nutritional status are associated with cancer survival.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Body mass index; France; Lung cancer; Mortality; Weight loss

Mesh:

Year:  2018        PMID: 30527193     DOI: 10.1016/j.lungcan.2018.07.005

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  10 in total

1.  Impact of weight loss on treatment with PD-1/PD-L1 inhibitors plus chemotherapy in advanced non-small-cell lung cancer.

Authors:  Taichi Miyawaki; Tateaki Naito; Michitoshi Yabe; Hiroaki Kodama; Naoya Nishioka; Eriko Miyawaki; Nobuaki Mamesaya; Haruki Kobayashi; Shota Omori; Kazushige Wakuda; Akira Ono; Hirotsugu Kenmotsu; Haruyasu Murakami; Keita Mori; Hideyuki Harada; Kazuhisa Takahashi; Toshiaki Takahashi
Journal:  Support Care Cancer       Date:  2021-09-22       Impact factor: 3.359

Review 2.  The Role of Malnutrition and Muscle Wasting in Advanced Lung Cancer.

Authors:  Rishi Jain; Chris Coss; Peter Whooley; Mitch Phelps; Dwight H Owen
Journal:  Curr Oncol Rep       Date:  2020-05-15       Impact factor: 5.075

3.  Postdiagnosis BMI Change Is Associated with Non-Small Cell Lung Cancer Survival.

Authors:  Qianyu Yuan; Mulong Du; Elizabeth Loehrer; Bruce E Johnson; Justin F Gainor; Michael Lanuti; Yi Li; David C Christiani
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2021-11-02       Impact factor: 4.090

4.  Body Mass Index, Weight Loss, and Mortality Risk in Advanced-Stage Non-Small Cell Lung Cancer Patients: A Focus on EGFR Mutation.

Authors:  Yu-Mu Chen; Chien-Hao Lai; Chiung-Yu Lin; Yi-Hsuan Tsai; Ya-Chun Chang; Hung-Chen Chen; Chia-Cheng Tseng; Huang-Chih Chang; Kuo-Tung Huang; Yung-Che Chen; Wen-Feng Fang; Chin-Chou Wang; Tung-Ying Chao; Meng-Chih Lin
Journal:  Nutrients       Date:  2021-10-24       Impact factor: 5.717

5.  Twenty-Year Survival of Patients Operated on for Non-Small-Cell Lung Cancer: The Impact of Tumor Stage and Patient-Related Parameters.

Authors:  Olivier Schussler; Antonio Bobbio; Hervé Dermine; Audrey Lupo; Diane Damotte; Yves Lecarpentier; Marco Alifano
Journal:  Cancers (Basel)       Date:  2022-02-10       Impact factor: 6.639

6.  Obesity is associated with improved postoperative overall survival, independent of skeletal muscle mass in lung adenocarcinoma.

Authors:  Ji Hyun Lee; Young Cheol Yoon; Hyun Su Kim; Min Jae Cha; Jae-Hun Kim; Kyunga Kim; Hye Seung Kim
Journal:  J Cachexia Sarcopenia Muscle       Date:  2022-02-25       Impact factor: 12.910

7.  Pretreatment body mass index predicts survival among patients administered nivolumab monotherapy for pretreated non-small cell lung cancer.

Authors:  Hisao Imai; Erika Naito; Ou Yamaguchi; Kosuke Hashimoto; Hidetoshi Iemura; Yu Miura; Ayako Shiono; Atsuto Mouri; Kyoichi Kaira; Kunihiko Kobayashi; Hiroshi Kagamu
Journal:  Thorac Cancer       Date:  2022-04-08       Impact factor: 3.223

8.  Weight and skeletal muscle loss with cabozantinib in metastatic renal cell carcinoma.

Authors:  Emeline Colomba; Carolina Alves Costa Silva; Gwénaël Le Teuff; Jamie Elmawieh; Daniel Afonso; Axelle Benchimol-Zouari; Annalisa Guida; Lisa Derosa; Ronan Flippot; Bruno Raynard; Bernard Escudier; François Bidault; Laurence Albiges
Journal:  J Cachexia Sarcopenia Muscle       Date:  2022-07-28       Impact factor: 12.063

9.  Pre-Disease and Pre-Surgery BMI, Weight Loss and Sarcopenia Impact Survival of Resected Lung Cancer Independently of Tumor Stage.

Authors:  Philippe Icard; Olivier Schussler; Mauro Loi; Antonio Bobbio; Audrey Mansuet Lupo; Marie Wislez; Antonio Iannelli; Ludovic Fournel; Diane Damotte; Marco Alifano
Journal:  Cancers (Basel)       Date:  2020-01-22       Impact factor: 6.639

10.  Cognitive impairment is related to a reduced count of T-lymphocytes in older patients diagnosed with non-small cell lung cancer (NSCLC).

Authors:  Teresa Soria-Comes; Vicente Palomar-Abril; María Martín Ureste; Javier García Sánchez; Josefa Esperanza Marco Buades; María José Fernández Llavador; Amparo López Gabaldón; Mar González Jurado; Inmaculada Concepción Maestu Maiques
Journal:  Transl Cancer Res       Date:  2020-11       Impact factor: 1.241

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.